6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging

Experimental Neurology

Volumn 192, Issue 1, 2005, Pages 194-202

  Kondoh, Takashi ^a   Bannai, Makoto ^a   Nishino, Hitoo ^b   Torii, Kunio ^a  

^a AJINOMOTO CO INC   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

6 hydroxydopamine; Dopamine; Hyperintensity; Magnetic resonance imaging; Parkinson's disease; Rotational behavior; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DESIPRAMINE; METHAMPHETAMINE; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; BRAIN REGION; BRAIN SIZE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EVALUATION; IMMUNOHISTOCHEMISTRY; INJECTION; MALE; MEDICAL INFORMATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATION; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 13444283720     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.12.016     Document Type: Article

References (24)

1. Y. Agid, F. Javoy, J. Glowinski, D. Bouvet, and C. Sotelo Injection of 6-hydroxydopamine into the substantia nigra of the rat: II. Diffusion and specificity Brain Res. 58 1973 291 301
2. J.K. Dhawan, V.M. Kumar, V. Govindaraju, and P. Raghunathan Changes in magnetic resonance imaging and sex behavior after 6-OHDA injection in the medial preoptic area Brain Res. Bull. 45 1998 333 339
3. W.R.G. Gibb Neuropathology of Parkinson's disease and related syndromes Neurol. Clin. 10 1992 361 376
4. R. Guzman, K.O. Lövblad, M. Meyer, C. Spenger, G. Schroth, and H.R. Widmer Imaging the rat brain on a 1.5 T clinical MR-scanner J. Neurosci. Methods 97 2000 77 85
5. B. Halliwell, J.M.C. Gutteridge, and C.E. Cross Free radicals, antioxidants and human disease: where are we now? J. Lab. Clin. Med. 119 1992 598 620
6. T. Hökfelt, and U. Ungerstedt Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurons: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system Brain Res. 60 1973 269 297
7. K. Jellinger Chapter 4. Synucleinopathies: experimental models of synucleinopathies D.W. Dickson Neurodegeneration 2003 ISN Neuropath Press, Basel 215 223
8. J. John, V. Govindaraju, P. Raghunathan, and V.M. Kumar Magnetic resonance imaging of temporal changes of neurotoxic lesion in the rat Brain Res. Bull. 40 1996 273 277
9. C. Kohler, R. Schwarcz, and K. Fuxe Intrahippocampal injections of ibotenic acid provide histological evidence for a neurotoxic mechanism different from kainic acid Neurosci. Lett. 15 1979 223 228
10. V.M. Kumar, J. John, V. Govindaraju, N.A. Khan, and P. Raghunathan Magnetic resonance imaging of NMDA-induced lesion of the medial preoptic area and changes in sleep, temperature and sex behaviour Neurosci. Res. 24 1996 207 214
11. C.S. Lee, H. Sauer, and A. Björklund Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat Neuroscience 72 1996 641 653
12. A. Lewen, P. Matz, and P.H. Chan Free radical pathways in CNS injury J. Neurotrauma 17 2000 871 890
13. T. Malmfors T. Malmfors H. Thoenen 6-Hydroxydopamine and Catecholamine Neurons 1971 North-Holland Amsterdam 353
14. D. Offen, P.M. Beart, N.S. Cheung, C.J. Pascoe, A. Hochman, S. Gorodin, E. Melamed, R. Bernard, and O. Bernard Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity Proc. Natl. Acad. Sci. U. S. A. 95 1998 5789 5794
15. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates, Compact Third ed. 1997 Academic Press San Diego
16. D.A. Perese, J. Ulman, J. Viola, S.E. Ewing, and K.S. Bankiewicz A 6-hydroxydopamine-induced selective parkinsonian rat model Brain Res. 494 1989 285 293
17. L.J. Poirier, P. Langelier, A. Roberge, R. Boucher, and A. Kitsikis Non-specific histopathological changes induced by the intracerebral injection of 6-hydroxy-dopamine (6-OH-DA) J. Neurol. Sci. 16 1972 401 416
18. S. Przedborski, M. Levivier, H. Jiang, M. Ferreira, V. Jackson-Lewis, D. Donaldson, and D.M. Togasaki Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine Neuroscience 67 1995 631 647
19. U. Pschorn, H. Korperich, L. Heymans, S. Subramanian, and W. Kuhn MRI and MRS studies on time course of lesions and the effect of drug treatment: volume of quantification and characterization of tissue heterogeneity by parameter selection Magn. Reson. Med. 30 1993 174 182
20. C. Sachs, and G. Jonsson Mechanisms of action of 6-hydroxydopamine Biochem. Pharmacol. 24 1975 1 8
21. C. Sotelo, F. Javoy, Y. Agid, and J. Glowinski Injection of 6-hydroxydopamine in the substantia nigra of the rat: I. Morphological study Brain Res. 58 1973 269 290
22. L. Thompson Fetal transplants show promise Science 257 1992 868 870
23. 1H nuclear magnetic resonance imaging Brain Res. 618 1993 203 212
24. C. Winkler, H. Sauer, C.S. Lee, and A. Björklund Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease J. Neurosci. 16 1996 7206 7215